BCL2 and B-cell chronic lymphocytic leukemia: Some of the current treatment options for CLL consist of BCL2 inhibitor Venetoclax, Bruton tyrosine kinase inhibitor ibrutinib, and the standard combination of fludarabine, cyclophosphamide, and rituximab [263].